High-Content Screening (HCS, also known as High-Content Analysis, or HCA) is an approach to cell biology that combines automated imaging and quantitative data analysis in a high-throughput format suitable for large-scale applications such as drug discovery and systems biology. The market refers to the sector of the life sciences industry that focuses on using advanced imaging and analysis techniques to study and analyze cellular processes and biological phenomena on a large scale. HCS involves the automated imaging and quantitative analysis of cells or organisms using technologies such as fluorescence microscopy, automated liquid handling systems, and sophisticated image analysis software.
Access Full Report at https://www.databridgemarketresearch.com/es/reports/global-high-content-screening-market
Data Bridge Market Research analyzes that the Global High Content Screening Market is expected to grow at a CAGR of 7.3% from 2023 to 2030 and is expected to reach USD 4,305,259.28 thousand by 2030. The growing number of CROs providing HCS services is expected to propel the market growth.
Key Findings of the Study
Advancement in Imaging Technologies Used for High Content Screening
Imaging technologies have been at the forefront of High-Content Screening (HCS), enabling researchers to visualize and analyze cellular processes with unprecedented detail and precision. In addition to high-resolution imaging, there have been significant improvements in imaging speed and throughput. HCS helps in the analysis of a large number of samples, often in high-throughput formats. Imaging technologies have evolved to provide faster acquisition times, enabling researchers to analyze large datasets in a shorter period. High-speed imaging techniques, such as spinning disk confocal microscopy and light-sheet microscopy, allow for rapid image acquisition without compromising image quality, facilitating efficient screening workflows and data analysis.
Over the years, significant advancements have been made in imaging modalities, microscopy techniques, and imaging analysis tools, transforming the landscape of HCS and driving its market expansion.
For instance,
- In January 2023, Axion BioSystems announced the addition of the Omni Pro 12 to the Omni live-cell imaging product family. The new platform, which features integrated robotics and multiple designs compatible with any standard incubator, offers enhanced flexibility and efficiency to scientists and drug developers conducting live-cell imaging experiments. This advancement in the imaging technique would help drug discovery be efficient by having live cell imaging experiments
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2016-2021 )
|
|
Quantitative Units
|
Revenue in USD, Pricing in USD
|
|
Segments Covered
|
By Product Type (Instruments, Consumables, Software, Services, and Accessories), Application (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, and Others), Technology (Microscopy, Flow Cytometry, Mass Spectrometry, Western Blotting, ELISA, Immunohistochemistry, and Others), End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutes, Contract Research Organizations, Laboratories, and Others), Distribution Channel (Direct Tenders and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Denmark, Netherlands, Switzerland, Sweden, Poland, Norway, Finland, Rest of Europe, Japan, China, India, South Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Oman, Qatar, Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
BD., Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, EVIDENT, Zifo RnD Solutions, Axxam S.p.A., Molecular Devices, LLC. (Subsidiary of Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, De Novo Software, Araceli Biosciences, Miltenyi Biotec, and Aligned Genetics, Inc. among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
The global high content screening market is segmented into five notable segments based on product type, application, technology, end user, and distribution channel.
- On the basis of product type, the market is segmented into instruments, consumables, software, services, and accessories.
In 2023, the instrument segment is projected to hold the largest market share of the product type segment in the global high content screening market
In 2023, the instruments segment is expected to dominate the market with a 30.04% market share, growing with a CAGR of 9.0% in the forecast period of 2023 to 2030.
- On the basis of application, the market is segmented into primary and secondary screening, target identification and validation, toxicity studies, compound profiling, and others.
In 2023, the primary and secondary screening segment of the application segment is expected to dominate the global high content screening market
In 2023, the primary and secondary screening segment is expected to dominate the market due to its ability to enable the identification and validation of potential drugs contributing to the drug discovery process.
- On the basis of technology, the market is segmented into microscopy, flow cytometry, mass spectrometry, western blotting, ELISA, immunohistochemistry, and others. In 2023, the microscopy segment is expected to dominate the market with a 26.45% market share, growing with a CAGR of 10.2% in the forecast period of 2023 to 2030
- On the basis of end user, the market is segmented into pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations, laboratories, and others. In 2023, the pharmaceutical and biotechnology companies segment is expected to dominate the market with a 37.15% market share, growing with a CAGR of 8.6% in the forecast period of 2023 to 2030
- On the basis of distribution channel, the market is segmented into direct tenders and retail sales. In 2023, the direct tenders segment is expected to dominate the market with a 63.97% market share, growing with a CAGR of 7.7% in the forecast period of 2023 to 2030
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the global high content screening market that include BD., Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, EVIDENT, Zifo RnD Solutions, Axxam S.p.A., Molecular Devices, LLC. (Subsidiary of Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, De Novo Software, Araceli Biosciences, Miltenyi Biotec, and Aligned Genetics, Inc. among others.
Market Developments
- In February 2023, PerkinElmer Inc. launched the EnVision Nexus system, its fastest and most sensitive multimode plate reader to date, designed for demanding High-Throughput Screening (HTS) applications and to accelerate drug discovery efforts. This product launch has helped the company in its product portfolio expansion. This helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the global presence in the market
- In February 2023, Agilent Technologies, Inc. announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems. This will help the company to strengthen its product portfolio in the market
- In October 2022, BD (Becton, Dickinson and Company), a leading global medical technology company, and Magnolia Medical Technologies, Inc. announced a co-exclusive commercial agreement aimed at helping the U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes. This has helped the company to get connected to various vendors and get established globally
- In January 2021, Corning Incorporated will highlight its latest technologies that support the advancement of 3D cell culture, automation, and drug discovery at this year's virtual Society for Laboratory Automation and Screening (SLAS) conference. This will help the company to expand its product portfolio
- In May 2023, Sysmex Corporation announced that it would launch its Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan, following the launch in North America, Europe, and Asia-Pacific regions. This product launch will help the company in product portfolio expansion
Regional Analysis
Geographically, the countries covered in the global high content screening market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Denmark, Netherlands, Switzerland, Sweden, Poland, Norway, Finland, Rest of Europe, Japan, China, India, South Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, Bahrain, U.A.E., Kuwait, Oman, Qatar, Egypt, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis
The global high content screening market is expected to grow at a CAGR of 7.3% due to rising strategic initiatives taken by market players.
For more detailed information about the global high content screening market, click here – https://www.databridgemarketresearch.com/es/reports/global-high-content-screening-market
